Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience went public on February 1, 2024. In October 2024, the stock fell nearly 64% after ALTO-100 failed to meet its primary endpoint in a Phase 2 study, leading to analyst downgrades. In October 2025, the company announced a $50 million private placement and received FDA Fast Track Designation for ALTO-101. In November 2025, Chardan Capital upgraded Alto Neuroscience to a "strong-buy" rating, and other analysts increased their price targets. The stock has shown significant increases, with a 400.74% increase over the past six months and a 218.22% increase over the past year as of November 27, 2025.

Information regarding specific demand seasonality for Alto Neuroscience's products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to research and development milestones and potential future product commercialization, rather than seasonal consumer demand.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on transforming psychiatric care through a neurobiology-driven approach to develop personalized and effective treatment options. The company utilizes its Precision Psychiatry Platform, which measures brain biomarkers through EEG activity, neurocognitive assessments, and wearable data, to identify patients most likely to respond to its product candidates. Its clinical-stage pipeline includes ALTO-100 in Phase 2b clinical trial for bipolar depression (BPD) and previously in Phase 2b for major depressive disorder (MDD), ALTO-300 in Phase 2b clinical trial for MDD, ALTO-101 in Phase 2 proof-of-concept (POC) trial for cognitive impairment associated with schizophrenia, ALTO-203 in Phase 2 POC trial for MDD with higher levels of anhedonia, ALTO-202 in Phase 1 clinical trial for MDD, and ALTO-207 and ALTO-208 as other product candidates in its clinical-stage pipeline.

Alto Neuroscience is headquartered in Mountain View, California, and operates as a clinical-stage biopharmaceutical company within the United States.

Alto Neuroscience's brand reputation has been influenced by both positive and negative events in the past year. The failure of the ALTO-100 Phase 2b trial for MDD in October 2024 significantly impacted its reputation, leading to a stock price drop and analyst downgrades. Conversely, the FDA Fast Track Designation for ALTO-101 in October 2025 highlights the potential of its pipeline. Analyst ratings average a "Moderate Buy," and recent upgrades from firms like Chardan Capital and increased price targets from Jefferies and Baird in November 2025 contribute positively to its brand perception.

Alto Neuroscience is owned by a mix of institutional shareholders (53.94%), Alto Neuroscience insiders (21.66%), and retail investors (24.40%). Major institutional shareholders include Alpha Wave Global LP, Armistice Capital LLC, Point72 Asset Management LP, Franklin Resources Inc, Vanguard Group Inc, Vestal Point Capital LP, Marshall Wace LLP, Falcon Edge Capital, LP, and BlackRock, Inc. Alpha Wave Global LP is the largest individual shareholder, holding 11.93% of the company's shares.